Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Cinacalcet

Cinacalcet

Cinacalcet: A Comprehensive Overview

Introduction to Cinacalcet

Cinacalcet is a medication primarily used in the management of hyperparathyroidism in certain patient populations, including those with chronic kidney disease (CKD) on dialysis and parathyroid carcinoma. As an allosteric modulator of the calcium-sensing receptor (CaSR), cinacalcet mimics the effects of calcium, enhancing the sensitivity of the receptor to extracellular calcium, which ultimately leads to decreased secretion of parathyroid hormone (PTH). Cinacalcet is a relatively newer medication in the realm of endocrinology, and its development has provided an effective tool for managing conditions that involve abnormal parathyroid hormone regulation.

Mechanism of Action of Cinacalcet

Cinacalcet acts as a calcimimetic agent, meaning it enhances the sensitivity of the calcium-sensing receptor (CaSR) on parathyroid cells to extracellular calcium. The CaSR is a G-protein coupled receptor that plays a crucial role in regulating calcium homeostasis by modulating the release of parathyroid hormone (PTH).

The Role of Calcium-Sensing Receptors (CaSR)

The CaSR is found on the surface of parathyroid cells, and it regulates PTH secretion in response to changes in extracellular calcium levels. When calcium levels rise, the CaSR is activated, leading to a decrease in PTH secretion. Conversely, when calcium levels fall, the CaSR is less active, and PTH secretion increases. This feedback loop helps to maintain stable calcium levels in the blood. In patients with secondary hyperparathyroidism (common in those with chronic kidney disease) or primary hyperparathyroidism, the parathyroid glands become less sensitive to normal fluctuations in calcium levels. This insensitivity results in the continuous overproduction of PTH, which exacerbates conditions like hypercalcemia and bone demineralization. Cinacalcet works by binding to and activating the CaSR, thereby increasing its sensitivity to calcium even when extracellular calcium levels are not high. This enhanced sensitivity reduces the secretion of PTH, even in the presence of lower calcium levels, thereby helping to normalize PTH levels and mitigate the harmful effects of elevated PTH.

Therapeutic Uses of Cinacalcet

Cinacalcet is used in the management of several conditions related to abnormal parathyroid hormone regulation. These conditions include secondary hyperparathyroidism (SHPT), primary hyperparathyroidism (PHPT), and parathyroid carcinoma. Cinacalcet is particularly beneficial in managing secondary hyperparathyroidism associated with chronic kidney disease (CKD).

1. Secondary Hyperparathyroidism (SHPT)

Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD), especially in patients on dialysis. In CKD, the kidneys lose their ability to excrete phosphate efficiently, leading to elevated phosphate levels and a decrease in serum calcium. This imbalance stimulates the parathyroid glands to release excess parathyroid hormone (PTH) in an attempt to maintain normal calcium levels.

However, the excess PTH can lead to bone mineralization disorders, vascular calcification, and other complications. Cinacalcet is used to lower elevated PTH levels in CKD patients by increasing the sensitivity of the CaSR, thereby reducing PTH secretion.

By lowering PTH levels, cinacalcet helps to:

  • Reduce the risk of hypercalcemia.

  • Improve bone mineral density.

  • Mitigate the effects of vascular calcification.

Cinacalcet has been shown to be effective in improving calcium-phosphate balance and decreasing the need for phosphate binders in CKD patients undergoing dialysis.

2. Primary Hyperparathyroidism (PHPT)

Primary hyperparathyroidism (PHPT) is a condition in which one or more of the parathyroid glands become overactive, resulting in elevated levels of PTH and calcium in the blood. This can lead to hypercalcemia, osteoporosis, kidney stones, and other complications. Although the primary treatment for PHPT is often surgical removal of the affected parathyroid gland(s), cinacalcet can be used as an adjunct for patients who are not candidates for surgery or those with severe disease.

Cinacalcet helps to reduce PTH levels in PHPT patients by enhancing the sensitivity of the CaSR to calcium. This helps to normalize calcium levels and improve bone health in individuals with PHPT.

3. Parathyroid Carcinoma

In parathyroid carcinoma, a rare form of cancer that affects the parathyroid glands, there is often overproduction of PTH. This can lead to severe hypercalcemia, which is difficult to manage. Cinacalcet can be used to lower PTH levels and control hypercalcemia in patients with parathyroid carcinoma who are not candidates for surgery or whose cancer is not amenable to resection.

Dosage and Administration of Cinacalcet

Cinacalcet is typically administered orally in the form of a tablet. The dosage of cinacalcet is tailored to the patient's condition, the severity of the disease, and the patient's response to treatment. It is important to adjust the dose based on parathyroid hormone (PTH) and calcium levels.

Dosage for Secondary Hyperparathyroidism (SHPT)

  • The starting dose is generally 30 mg once daily.

  • The dose can be titrated upwards based on PTH levels and calcium levels, with a maximum dose of 180 mg per day.

  • The dose should be adjusted in increments of 30 mg based on the patient's response, with regular monitoring of serum calcium and PTH levels.

Dosage for Primary Hyperparathyroidism (PHPT)

  • The typical starting dose for PHPT is 30 mg once daily.

  • Depending on response, the dose can be adjusted upwards to a maximum of 180 mg per day.

Dosage for Parathyroid Carcinoma

  • For parathyroid carcinoma, the starting dose is 30 mg once daily, and the dose may be titrated upward to achieve optimal control of PTH and calcium levels.

Adjustments in Renal Impairment

  • Cinacalcet is metabolized in the liver, but it is primarily excreted through the kidneys. In patients with renal impairment, it is important to monitor serum calcium levels closely.

  • No dosage adjustment is needed for patients with mild to moderate renal impairment. However, severe renal impairment may require careful dose adjustments.

Side Effects of Cinacalcet

While cinacalcet is generally well-tolerated, it can cause side effects, some of which may be serious. Common and less common side effects of cinacalcet include:

1. Common Side Effects

  • Hypocalcemia: The most common side effect of cinacalcet is low calcium levels (hypocalcemia), which can cause symptoms such as muscle spasms, cramps, tingling in the lips or fingers, and in severe cases, seizures.

  • Nausea and vomiting: Some patients may experience gastrointestinal symptoms, including nausea and vomiting, particularly at higher doses.

  • Diarrhea: Diarrhea is another gastrointestinal side effect that some patients may experience.

2. Less Common Side Effects

  • Fatigue: Some patients report feeling tired or fatigued while taking cinacalcet.

  • Headache: Headaches can occur in a subset of patients, though they are generally mild.

  • Chest pain: A small number of patients may experience chest pain while using cinacalcet.

3. Serious Side Effects

  • Severe Hypocalcemia: Severe hypocalcemia can lead to life-threatening complications, including cardiac arrhythmias and seizures. Regular monitoring of calcium levels is crucial during cinacalcet therapy.

  • QT Interval Prolongation: Cinacalcet may prolong the QT interval on an electrocardiogram (ECG), which can increase the risk of arrhythmias, particularly in patients with other underlying cardiac conditions.

4. Drug Interactions

  • Cinacalcet may interact with certain medications, including CYP3A4 inhibitors and CYP2D6 inhibitors, which can increase cinacalcet levels in the blood.

  • Drugs that lower calcium levels or are associated with hypocalcemia (e.g., bisphosphonates or calcitonin) should be used with caution in conjunction with cinacalcet.

Clinical Evidence and Efficacy

Several clinical studies and trials have demonstrated the efficacy and safety of cinacalcet in treating hyperparathyroidism.

1. Efficacy in Secondary Hyperparathyroidism

  • In a large clinical trial involving patients with CKD on dialysis, cinacalcet was shown to significantly reduce PTH levels, leading to improved control of calcium-phosphate metabolism. Additionally, cin

acalcet therapy was associated with decreased risk of vascular calcification and improved bone mineralization.

2. Efficacy in Primary Hyperparathyroidism

  • In patients with PHPT who are not candidates for surgery, cinacalcet has been shown to significantly reduce serum calcium and PTH levels, thus helping to prevent the complications of hypercalcemia, such as bone loss and kidney stones.

3. Efficacy in Parathyroid Carcinoma

  • Cinacalcet has demonstrated benefit in patients with parathyroid carcinoma, helping to control severe hypercalcemia and improve quality of life in cases where surgery is not an option.

Conclusion

Cinacalcet is an important pharmacological tool in managing hyperparathyroidism, particularly in patients with chronic kidney disease, primary hyperparathyroidism, and parathyroid carcinoma. By enhancing the sensitivity of the calcium-sensing receptor, cinacalcet helps regulate PTH secretion and maintain calcium balance, ultimately improving patient outcomes. Despite its potential for side effects, particularly hypocalcemia, cinacalcet remains a critical therapy for patients who require PTH control and calcium regulation. Regular monitoring of calcium and PTH levels is essential to minimize risks and ensure optimal therapeutic efficacy. As research and clinical experience with cinacalcet continue to expand, its role in managing parathyroid disorders will likely grow, offering additional treatment options for patients with complex endocrine conditions.

Avaiable Medicines